Development of the new potent non-peptide gpIIb/IIIa antagonist NSL-95301 by utilizing combinatorial technique

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 2, 1997, Pages 209-212

  Harada, Takeo ^a   Katada, Jun ^a   Tachiki, Akira ^a   Asari, Tohru ^a   Iijima, Kiyoko ^a   Uno, Isao ^a   Ojima, Iwao ^b   Hayashi, Yoshio ^a  

^a NIPPON STEEL CORPORATION   (Japan)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 (4 AMIDINOBENZAMIDO) 2,2 DIMETHYL 3 PHENYLPROPIONYL]PIPERIDINE 4 ACETIC ACID; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; CONFORMATION; DRUG STRUCTURE; DRUG SYNTHESIS; TECHNIQUE; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0031031681     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(96)00610-5     Document Type: Article

References (29)

1. a)Pierschbacher, M. D.; Ruoslahti, E. Nature 1984, 309, 30.
2. b) Pierschbacher, M. D.; Ruoslahti, E. Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 5985.
3. c) Yamada, K. N.; Kennedy, D. W. J. Cell. Biol. 1984, 99, 29.
4. d) Humphries, M. J. J. Cell. Sci., 1995, 97, 585
5. a) Nichols, A.J.; Ruffolo Jr., R. R.; Huffman, W. F.; Poste, G.; Samanen, J. TiPS, 1992, 13, 413.
6. b) Frishman, W. H.; Burns, B.; Atac, B.; Alturk, N.; Altajar, B.; Lerrick, K. Am. Heart J. 1995, 130, 877.
7. c) Ojima, I.; Dong, Q.; Eguchi, M.; Oh, Y-i.; Amann, C. M.; Coller, B. S. Bioorg. Med. Chem. Lett. 1994, 4, 1749.
8. d) Ojima, I.; Dong, Q.; Chakravarty, S.; Peerschke, E.; Hwang, S. M.; Wong, A. S. Bioorg. Med. Chem. Lett. 1995, 5, 1941.
9. e) Newham, P.; Humphries, M. Mol. Med. Today 1996, Jul., 304.
10. Rouslahti, E.; Pierschbacher, M. D. Science, 1987, 238, 491
11. a) Falk, E. Circulation, 1985, 77, 699.
12. b) Coller, B.S. New England J. Med. 1990, 322, 33.
13. c) Cadroy, Y.; Harker, L. A. In Cardiovascular Pharmacology 3rd. Ed. ; M. Antonaccio, Ed.; Raven Press: New York, 1990: pp 515-539.
14. d) Schart, R. E.; Harker, L. A. Blut, 1987,509, 118.
15. a) Hayashi, Y.; Sato, Y.; Katada, J.; Takiguchi, Y.; Ojima, I.; Uno, I. Bioorg. Med. Chem. Lett. 1996, 6, 1351.
16. b) The other manuscripts are in preparation.
17. a) Bach II, A. C.; Eyermann, C. J.; Gross, J. D.; Bower, M. J.; Harlow, R. L.; Weber, D. C.; DeGrado, W. F. J. Am. Chem. Soc. 1994, 116, 3207.
18. b) McDowell, R. S.; Blackburn, B. K.; Gadek, T. R.; McGee, L. R.; Rawson, T.; Reymond, M. E.; Robarge, K. D.; Somers, T. C.; Thorsett, E. D.; Tischer, M.; Webb II, R. R.; Venuti, M.C. J. Am. Chem. Soc. 1994, 116, 5077.
19. c) McDowell, R. S.; Gadek, T. R.; Barker, P. L.; Burdick, D. J.; Chan, K. S.; Quan, C. L.; Skelton, N.; Struble, M.; Thorsett, E. D.; Tischer, M.; Tom, J. Y. K.; Webb, T. R.; Burnier, J. P. J. Am. Chem. Soc. 1994, 116, 5069.
20. d) Tung, J. S.; Jakubowski, J. A.; Heath, W. F.; Utterback, B. G.; Herron, D. K. Receptor, 1993, 3, 343.
21. e) McDowell, R. S.; Gadek, T. R. J. Am. Chem. Soc. 1992, 114, 9245.
22. f) Peishoff, C. E.; Ali, F. E.; Bean, J. W.; Calvo, R.; D'Ambrosio, C. A.; Eggleston, D. S.; Hwang, S. M.; Romoff, T.; Samanen, J. M.; Stadel, J.; Vasko, J. A.; Kopple, K. D. J. Med. Chem. 1992, 35, 3962.
23. g) Kopple, K. D.; Bauers, P. W.; D'Ambrosio, C. A.; Hughes, J. L.; Peishoff, C. E.; Eggleston, D. S. J. Am. Chem. Soc., 1992, 114, 9615.
24. h) Bogusky, M. J; Naylor, A. M.; Pitzenberger, S. M.; Nutt, R. F.; Brady, S. F.; Colton, C. D.; Sisko, J. T.; Anderson, P. S.; Veber, D. F. Int. J. Peptide Protein Res. 1992, 59, 63.
25. All compounds were synthesized on ABI-431A peptide synthesizer based on Fast-Moc™ method using Fmoc-chemistry and purified over ODS reverse phase HPLC.
26. 50 value is determined as the concentration of the sample required to achieve 50% inhibition.
27. +)
28. SUMICHIRAL OA-4700 (5 μm, 4.3 mmø × 250 mm) Hexane/THF/MeOH/TFA =70/20/10/0.2
29. +Nippon Steel Chemical Co.